Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia

Abstract Background Elderly patients with relapsed and refractory acute lymphoblastic leukemia (ALL) have poor prognosis. Autologous CD19 chimeric antigen receptor-modified T (CAR-T) cells have potentials to cure patients with B cell ALL; however, safety and efficacy of allogeneic CD19 CAR-T cells are still undetermined. Case presentation We treated a 71-year-old female with relapsed and refractory ALL who received co-infusion of haplo-identical donor-derived CD19-directed CAR-T cells and mobilized peripheral blood stem cells (PBSC) following induction chemotherapy. Undetectable minimal residual disease by flow cytometry was achieved, and full donor cell engraftment was established. The transient release of cytokines and mild fever were detected. Significantly elevated serum lactate dehydrogenase, alanine transaminase, bilirubin and glutamic-oxalacetic transaminase were observed from days 14 to 18, all of which were reversible after immunosuppressive therapy. Conclusions Our preliminary results suggest that co-infusion of haplo-identical donor-derived CAR-T cells and mobilized PBSCs may induce full donor engraftment in relapsed and refractory ALL including elderly patients, but complications related to donor cell infusions should still be cautioned. Trial registration Allogeneic CART-19 for Elderly Relapsed/Refractory CD19+ ALL. NCT0279955

Assessment of the Quality of Reporting in Abstracts of Randomized Controlled Trials Published in Five Leading Chinese Medical Journals

BACKGROUND: Clear, transparent and sufficiently detailed abstracts of randomized trials (RCTs), published in journal articles are important because readers will often base their initial assessment of a trial on such information. However, little is known about the quality of reporting in abstracts of RCTs published in medical journals in China. METHODS: We identified RCTs abstracts from 5 five leading Chinese medical journals published between 1998 and 2007 and indexed in MEDLINE. We assessed the quality of reporting of these abstracts based on the Consolidated Standards of Reporting Trials (CONSORT) abstract checklist. We also sought to identify whether any differences exist in reporting between the Chinese and English language version of the same abstract. RESULTS: We identified 332 RCT abstracts eligible for examination. Overall, the abstracts we examined reported 0-8 items as designated in the CONSORT checklist. On average, three items were reported per abstract. Details of the interventions (288/332; 87%), the number of participants randomized (216/332; 65%) and study objectives (109/332; 33%) were the top three items reported. Only two RCT abstracts reported details of trial registration, no abstracts reported the method of allocation concealment and only one mentioned specifically who was blinded. In terms of the proportion of RCT abstracts fulfilling a criterion, the absolute difference (percentage points) between the Chinese and English abstracts was 10% (ranging from 0 to 25%) on average, per item. CONCLUSIONS: The quality of reporting in abstracts of RCTs published in Chinese medical journals needs to be improved. We hope that the introduction and endorsement of the CONSORT for Abstracts guidelines by journals reporting RCTs will lead to improvements in the quality of reporting

Expert Consensus on Microtransplant for Acute Myeloid Leukemia in Elderly Patients -Report From the International Microtransplant Interest Group

Recent studies have shown that microtransplant (MST) could improve outcome of patients with elderly acute myeloid leukemia (EAML). To further standardize the MST therapy and improve outcomes in EAML patients, based on analysis of the literature on MST, especially MST with EAML from January 1st, 2011 to November 30th, 2022, the International Microtransplant Interest Group provides recommendations and considerations for MST in the treatment of EAML. Four major issues related to MST for treating EAML were addressed: therapeutic principle of MST (1), candidates for MST (2), induction chemotherapy regimens (3), and post-remission therapy based on MST (4). Others included donor screening, infusion of donor cells, laboratory examinations, and complications of treatment

Identification of RCT abstracts from the Chinese Biomedical Database.

<p>Identification of RCT abstracts from the Chinese Biomedical Database.</p

Number of abstracts identified and included from five Chinese medical journals.

<p>Data of impact factor and total citations are from the China Journal Citation Reports (CJCR) in 2007.</p

A Novel Pb-Resistant Bacillus subtilis Bacterium Isolate for Co-Biosorption of Hazardous Sb(III) and Pb(II): Thermodynamics and Application Strategy

The present work is the first to study co-biosorption of Pb(II) and Sb(III) by a novel bacterium and its application strategy. The biosorption characteristics of Pb(II) and Sb(III) ions from aqueous solution using B. subtilis were investigated. Optimum pH, biomass dosage, contact time and temperature were determined to be 5.00, 6.00 mg/L, 45 min and 35 °C, respectively. Langmuir, Freundlich, Temkin and Dubinin-Radushkevich (D-R) models were applied to describe the biosorption isotherm of the metal ions by B. subtilis. Results showed that Langmuir model fitted the equilibrium data of Pb(II) better than others, while biosorption of Sb(III) obeyed the Freundlich model well. The biosorption capacity of B. subtilis biomass for Pb(II) and Sb(III) ions was found to be 17.34 ± 0.14 and 2.32 ± 0.30 mg/g, respectively. Kinetic data showed the biosorption process of Pb(II) and Sb(III) ions both followed the pseudo-second-order kinetic model, with R2 ranging from 0.974 to 0.999 for Pb(II) and from 0.967 to 0.979 for Sb(III). The calculated thermodynamic parameters, negative ∆G and positive ∆H and ∆S values, indicated the biosorption of Pb(II) and Sb(III) ions onto B. subtilis biomass in water was feasible, endothermic, and spontaneous. Bacterial bioleaching experiment revealed B. subtilis can increase the mobility of Pb(II) and Sb(III) in polluted soil when pH was close to 6 at low temperature. Consequently, B. subtilis, as a cheap and original bacterial material, could be a promising biomass to remove Pb or isolate Sb from industrial wastewater and to assist phytoremediation of Pb and Sb from weak acid or near neutral pH polluted soils at low temperature